FDA approval paves the way for AcouSort’s first OEM commercialization within critical care diagnostics
AcouSort AB (publ) (“AcouSort”, the “Company”) today announces that the Company and its partner within critical care diagnostics have updated their collaboration agreement. The updated agreement follows the FDA approval in the fall of 2023 for the partnering company’s next generation point-of-care diagnostic system containing AcouSort’s acoustofluidics technology. Minimum revenues from the partnership in 2024 are expected to reach approximately SEK 3.5M.
Read the press release here.
Läs pressmeddelandet här.